Some doctors are seeking early access to Lilly’s retatrutide
Adobe
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health. Confidential tips can be sent on Signal at lizzylaw.53.Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Last month, STAT reported that Eli Lilly granted a single 79-year-old patient special access to retatrutide, an unapproved obesity drug that has demonstrated bariatric-surgery levels of weight loss.
Since then, at least a handful of clinicians have tried to seek the same access for their patients. Two of them haven’t received answers from the drugmaker for weeks; one heard back on Monday, only after STAT reached out to Lilly with questions for this story, that his patient might qualify for access to the drug.
